Yield of CD4+ T-cell subsets in GVHD target organs 13 days after HCT (mean ± SE 10−3; n = 4)
| . | Gut . | Liver . | Lung . | Skin . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Th1 . | Th2 . | Th17 . | Th1 . | Th2 . | Th17 . | Th1 . | Th2 . | Th17 . | Th1 . | Th2 . | Th17 . | |
| WT | 30.6 ± 3.5 | 2.7 ± 0.9 | 1.1 ± 0.1 | 498.0 ± 85.1 | 160.5 ± 39.5 | 9.3 ± 1.8 | 64.2 ± 13.9 | 41.7 ± 10.6 | 1.9 ± 0.5 | 80.0 ± 17.5 | 67.5 ± 12.1 | 2.4 ± 0.7 |
| IFN-γ−/− | NA | 1.6 ± 0.2 | 0.7 ± 0.2 | NA | 149.5 ± 13.4 | 35.9 ± 2.4 | NA | 410.5 ± 29.5 | 116.8 ± 10.5 | NA | 365.5 ± 32.1 | 45.1 ± 12.1 |
| IFN-γ−/− IL-17−/− | NA | 1.5 ± 0.6 | NA | NA | 189.5 ± 13.4 | NA | NA | 684.3 ± 102.6 | NA | NA | 280.5 ± 21.0 | NA |
| . | Gut . | Liver . | Lung . | Skin . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Th1 . | Th2 . | Th17 . | Th1 . | Th2 . | Th17 . | Th1 . | Th2 . | Th17 . | Th1 . | Th2 . | Th17 . | |
| WT | 30.6 ± 3.5 | 2.7 ± 0.9 | 1.1 ± 0.1 | 498.0 ± 85.1 | 160.5 ± 39.5 | 9.3 ± 1.8 | 64.2 ± 13.9 | 41.7 ± 10.6 | 1.9 ± 0.5 | 80.0 ± 17.5 | 67.5 ± 12.1 | 2.4 ± 0.7 |
| IFN-γ−/− | NA | 1.6 ± 0.2 | 0.7 ± 0.2 | NA | 149.5 ± 13.4 | 35.9 ± 2.4 | NA | 410.5 ± 29.5 | 116.8 ± 10.5 | NA | 365.5 ± 32.1 | 45.1 ± 12.1 |
| IFN-γ−/− IL-17−/− | NA | 1.5 ± 0.6 | NA | NA | 189.5 ± 13.4 | NA | NA | 684.3 ± 102.6 | NA | NA | 280.5 ± 21.0 | NA |
GVHD indicates graft-versus-host disease; HCT, hematopoietic cell transplantation; and NA, not applicable.